title: Effects of hyperglycemia on the development of new-onset diabetes after liver transplantation.
abstract: BACKGROUND
  New-onset diabetes after transplantation (NODAT) has been associated with cardiovascular and thrombotic complications, acute rejection, and infection in transplant recipients. NODAT in kidney transplantation is well described; however, data are lacking in liver transplant recipients.
  
  
  OBJECTIVE
  To evaluate the incidence of new-onset diabetes within 6 months postoperatively in adult liver transplant recipients. DESIGN, PARTICIPANTS, SETTING, AND INTERVENTIONS: Patients who underwent a liver transplantation at our institution between January 2004 and December 2005 were retrospectively evaluated. NODAT was defined according to the diagnostic criteria of the American Diabetes Association/World Health Organization, persistent hyperglycemia (serum glucose > or = 200 mg/dL occurring 2 weeks after initial steroid induction and persisting for more than 2 weeks), or the need for hypoglycemic agents upon discharge.
  
  
  RESULTS
  Incidence of NODAT within 6 months after transplantation in patients with poor glycemic control within the first 2 weeks after transplantation, acute rejection episodes, infections, hospital readmissions, and cardiovascular and thrombotic events.
  
  
  RESULTS
  Forty-five patients were evaluated. Within the first 6 months after transplantation, NODAT developed in 11 (24%). Acute rejection, infection, hospital readmissions, cardiovascular events, and thrombotic events did not differ between the groups.
  
  
  CONCLUSIONS
  Elevated fasting levels of blood glucose during the first 2 weeks after liver transplantation may be associated with an increased incidence of NODAT and may have predictive value. More studies are needed to determine the effects of recognition and treatment of hyperglycemia in recent transplant recipients.
authors.affiliation: University of Kentucky, Lexington, USA. april.anderson@orlandohealth.com
authors.forename: April L
authors.initials: AL
authors.lastname: Anderson
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Lewis
authors.forename: Douglas T
authors.initials: DT
authors.lastname: Steinke
authors.forename: Dinesh
authors.initials: D
authors.lastname: Ranjan
authors.forename: Kelly M
authors.initials: KM
authors.lastname: Smith
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Clifford
mesh_terms: D003920:Diabetes Mellitus / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006084:Graft Rejection / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced* / Q000150:complications; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015994:Incidence; D016031:Liver Transplantation; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology; D011184:Postoperative Period; D011379:Prognosis; D012189:Retrospective Studies; D012306:Risk; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood; D014481:United States / Q000453:epidemiology
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016559:Tacrolimus; D008775:Methylprednisolone